Physician profile
Mark Folk
NPI 1528060001
$4,419.18
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,010 · 2020: $599 · 2021: $919 · 2022: $969 · 2023: $923.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $916 · Education: $6.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $915.88 |
| Education | $6.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $766.33 | 2019-2023 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $715.56 | 2019-2023 | Farxiga, Breztri |
| Glaxosmithkline, LLC. | $478.20 | 2019-2023 | Trelegy Ellipta, Shingrix, Pediarix |
| Lilly USA, LLC | $433.87 | 2019-2023 | Jardiance, Mounjaro, Emgality |
| Boehringer Ingelheim Pharmaceuticals, INC. | $345.91 | 2019-2023 | Tradjenta, Synjardy, Jardiance |
| Abbvie INC. | $295.23 | 2021-2023 | |
| Pfizer INC. | $242.06 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $208.45 | 2019-2023 | Gardasil 9, Pneumovax 23, Vaxneuvance |
| Sanofi-Aventis U.S. LLC | $157.53 | 2020-2022 | |
| Amgen INC. | $156.25 | 2019-2023 | Repatha, Otezla |
| Teva Pharmaceuticals USA, INC. | $120.00 | 2019-2021 | |
| Sanofi Pasteur INC. | $93.82 | 2019-2023 | |
| Abbott Laboratories | $83.32 | 2021-2023 | Freestyle Libre 3 |
| Seqirus USA INC | $58.92 | 2022-2023 | Fluad Quadrivalent, Flucelvax Quadrivalent |
| Exact Sciences Corporation | $44.46 | 2023 | Cologuard Collection Kit |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company Ltd. | $40.11 | 2022 | |
| Allergan, INC. | $39.39 | 2019-2020 | |
| Amarin Pharma, INC. | $30.25 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $27.30 | 2020-2023 | |
| Linus Health, INC. | $20.96 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.70 | 2023 | |
| Genentech USA, INC. | $16.51 | 2021 | |
| Janssen Pharmaceuticals, INC | $12.72 | 2019 | |
| Astellas Pharma US INC | $12.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Folk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.